Suche
Filter by content type
Filter by content year
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
März 10, 2026 - … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, …
BioNTech veröffentlicht am 10. März 2026 Ergebnisse für das vierte Quartal und das Geschäftsjahr 2025 und informiert über operativen Fortschritt
Februar 24, 2026 - … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), …
BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
Februar 24, 2026 - … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, …
BioNTech ernennt Kylie Jimenez zur neuen Personalvorständin
Januar 28, 2026 - … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), …
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
Januar 28, 2026 - … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, …
BioNTech und OncoC4 erhalten Orphan-Drug-Status der FDA für Gotistobart bei Patientinnen und Patienten mit Plattenepithelkarzinom der Lunge
Januar 12, 2026 - … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), …
BioNTech and OncoC4 Receive FDA Orphan Drug Designation for Gotistobart in Squamous Non-Small Cell Lung Cancer
Januar 12, 2026 - … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, …
BioNTech erhält Fast-Track-Status der FDA für mRNA-Krebsimmuntherapie-Kandidat BNT113 bei HPV16+ Kopf- und Halskrebs
Januar 21, 2026 - … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), …
BioNTech Receives FDA Fast Track Designation for mRNA Cancer Immunotherapy Candidate BNT113 in HPV16+ Head and Neck Cancer
Januar 21, 2026 - … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, … including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genmab, …
BioNTech präsentiert auf der 44. J.P. Morgan Healthcare-Konferenz Updates zur Geschäftsentwicklung und Schwerpunkte für das Jahr 2026
Januar 12, 2026 - … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), … darunter Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (ein Unternehmen der Roche Gruppe), …
